Thursday, March 20, 2014

Ziopharm climbs 12% after $11 price target from Mizuho Financial Group

This may be the first Mizuho Financial Group price target that I've seen in the biotech industry in my 20 years of trading - I'd take this price target with a grain of salt.  Ziopharm has a drug in phase 2 trials which will report around the end of the year but they are a long way from commercializing anything (if ever) and already carry a heft $540 million+ market cap.

No comments:

Post a Comment

Thank you for your contribution to BiotechInvestor.com